#China #Suzhou #Ribo Life Science #RNA Leaders #RiboPepSTAR

Ribo Life Science's New Breakthrough: RiboPepSTAR™

Suzhou Ribo Life Science Co., Ltd. has made headlines recently after being invited to speak at the RNA Leaders Europe Conference in Vienna, Austria. Ribo's latest innovation, RiboPepSTAR™, is redefining the landscape of small interfering RNA (siRNA) delivery by enabling precise administration to multiple organs, transcending the limitations of liver-centric therapies.

Advancements Beyond the Liver

Having previously found tremendous success with RiboGalSTAR™, which has backed seven clinical programs and global partnerships worth over $6 billion, Ribo now aims to expand its multi-target platforms beyond hepatic applications.

RiboPepSTAR™ promises a transformative approach in gene silencing, presenting impressive preclinical data across various tissues.

Kidney Targeting

Preclinical studies utilizing RiboPepSTAR™ demonstrated selective absorption in proximal tubular cells. The results were striking, showcasing up to an 80% reduction in target gene expression across models that included rodents and non-human primates. In physiologically relevant disease models, such as type 2 diabetes, RiboPepSTAR™ facilitated substantial decreases in renal-specific biomarkers. Encouragingly, Ribo's first renal-targeting drug has now progressed to research new drug authorization.

Cardiac Targeting

In cardiac studies using mouse models, RiboPepSTAR™ illustrated significant and sustained gene expression reductions within the heart. Notably, minimal impact was recorded in muscle tissue and negligible activity was observed within the liver and kidneys, highlighting the cardiac specificity the technology offers.

Adipose Tissue Targeting

Non-human primate trials exhibited RiboPepSTAR™'s potential to effectively target adipose tissue, achieving a remarkable 96% reduction in expression levels. This finding suggests immense possibilities in managing metabolic disorders.

Efficacy of Multi-Target Platforms

In addition to these developments, Ribo is advancing a multi-target siRNA platform. This initiative allows a single molecule to silence two or more genes simultaneously. Ribo’s dual-target siRNAs show comparable levels of expression reduction to single-target molecules, enabling synergistic pathway modulation and enhancing therapeutic benefits with one treatment entity.

The exclusive multi-target platforms moving beyond liver applications from Ribo pave the way for first-class therapies across a spectrum of pathologies, aligning seamlessly with Ribo’s commitment to delivering next-generation siRNA-based drugs to patients worldwide.

Conclusion

With RiboPepSTAR™ leading the charge, Ribo Life Science stands poised to revolutionize the field of RNA therapeutics. As the company continues to innovate and expand, the implications for treating diseases affecting the kidneys, heart, and metabolic systems are profound. The future holds great promise as Ribo ventures into new territories in gene therapy, making significant strides towards better health outcomes globally.